

Takeda Oncology Pipeline

Our research and development efforts focus on advancing medicines for hematologic, thoracic and gastrointestinal cancers by leveraging modalities best suited to make a difference in the treatment of these diseases. Our core modalities include antibody-drug conjugates (ADCs), complex biologics and small molecules.

These therapies in development are investigational and have not been approved by any regulatory bodies for use in the investigational indications listed below.

INVESTIGATIONAL THERAPY	MODALITY	INVESTIGATIONAL INDICATION	PHASE	ADDITIONAL INFORMATION
Elritercept (TAK-226)	Complex biologic	<i>Second-line anemia-associated myelodysplastic syndromes</i>	Phase 3 	Takeda has development and commercialization rights for the treatment worldwide outside of mainland China, Hong Kong and Macau. Activin A/B ligand trap
		<i>Anemia-associated myelofibrosis</i>	Phase 2 	
Mirvetuximab soravtansine-gynx (TAK-853)	ADC	<i>Folate receptor alpha (FRα)-positive platinum-sensitive ovarian cancer (JP)</i>	Phase 3 	Takeda has development and commercialization rights for the treatment in Japan.
		<i>Folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (JP)</i>	Phase 1/2 	
Rusfertide (TAK-121)	Small molecule	<i>Polycythemia vera (USA)</i>	Phase 3 	Collaboration with Protagonist Therapeutics. Protagonist is responsible for development in the U.S. through the completion of the Phase 3 VERIFY trial. Takeda has rights for ex-U.S. development and is responsible for leading global regulatory and commercialization activities. Hepcidin mimetic peptide (injection)
TAK-921	ADC	<i>3L+ gastric cancer (JP)</i>	Phase 3 	Collaboration with Innovent Biologics. Takeda has development and commercialization rights for the treatment worldwide outside of mainland China, Hong Kong, Macau and Taiwan.
		<i>Solid tumors</i>	Phase 1 	
TAK-928	Complex biologic	<i>2L squamous non-small cell lung cancer</i>	Phase 3 	Collaboration with Innovent Biologics. Takeda will lead global co-development and U.S. co-commercialization and has exclusive commercial rights outside the U.S. and mainland China, Hong Kong, Macau and Taiwan.
		<i>Solid tumors</i>	Phase 2 	
TAK-188	ADC	<i>Solid tumors</i>	Phase 1/2 	Takeda has global development and commercialization rights to TAK-188, which utilizes licensed technology from Heidelberg Pharma and Memorial Sloan Kettering Cancer Center.
TAK-168	Small molecule	<i>Solid tumors</i>	Phase 1 	Collaboration with Kumquat Biosciences. Kumquat is responsible for development (KQB168) through the completion of the Phase 1 trial (NCT06994806).

All programs have global development rights unless otherwise noted.

GL = global (USA, Europe, Japan, China) / EU = Europe / JP = Japan / CN = China / GEM = global emerging markets.



Learn more at [TakedaOncology.com](https://www.takedaoncology.com)

©2026 Takeda Pharmaceuticals U.S.A., Inc.



ONCOLOGY